Risk screening for FXS is based on FMR1 mutations defined by a normal or common range (CGGn<45), an intermediate or gray zone range between approximately CGGn=45–54 and a premutation range of approximately CGG n=55–200. This evidence concerns the gene FMR1 and fragile X syndrome.